GSK says US FDA approves Hibsago for chronic hepatitis B
GSK•GSK said the US FDA approved Hibsago for chronic hepatitis B. The company said it continues to advance regulatory submissions for bepirovirsen across multiple geographies.
1. FDA approval
GSK said the US FDA approved Hibsago for chronic hepatitis B. The company also said it continues to advance regulatory submissions for bepirovirsen across multiple geographies.
